drugset / Trial / NCT01108055
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
NaSingle-groupOpen-labelTreatment
Summary
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.
Timeline
- Start
- 2010-04
- Primary completion
- 2015-01
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |